Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. CS5001 is well tolerated in heavily pre-treated patients with advanced B-cell lymphoma. No dose-limiting toxicity (DLT) has been reported up...
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced updated Phase 1 study results of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced pancreatic ductal...
Riyadh International Philosophy Conference 2024 Concludes with a Focus on Quality of Life
Day 3 explored the philosophical contributions to the quality of life, and the ethical implications of AI and its impact on human life RIYADH, Saudi Arabia, Dec. 8, 2024 /PRNewswire/ -- The Riyadh International Philosophy Conference 2024 concluded its third and final day with a series of thought-provoking sessions exploring the theme of quality of life. The three-day event...
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth. This year, EpiVax expanded the breadth of its immunogenicity risk assessment services with the launch of many new...
Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices
NEW TAIPEI CITY, Dec. 7, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index, two prestigious benchmarks jointly compiled by FTSE Russell and the Taiwan Stock Exchange (TWSE). Effective December 23,...
Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations
BEIJING, Dec. 6, 2024 /PRNewswire/ -- Qi Biodesign, a biotechnology company pioneering next-generation genome editing technologies, announced the completion of its Series A funding round. The company has now raised a total of $75 million across its Seed, Series Pre-A, and Series A stages. The Series A round was led by the Beijing Medical and Health Care Industry Investment...
Another star technology platform of the Sanyou AI-STAL family
——Introducing Sanyou Mrna Mab innovative antibody generation technology platform SHANGHAI, Dec. 6, 2024 /PRNewswire/ -- With the announcement of the 2024 Nobel Prize in Physiology or Medicine, microRNA has once again become the focus of global attention. In the past 20 years, three Nobel Prizes have been awarded to the field of RNA molecular research, namely "RNA interference mechanism - double-stranded...
Empowering Lives, One Act of Kindness at a Time
Flood Relief for 147 Families in Need KUALA LUMPUR, Malaysia, Dec. 6, 2024 /PRNewswire/ -- Though the rain may have been relentless, USANA Foundation has once again proven that the power of community-driven initiatives can bring real, lasting change. Our commitment to standing by those in need has shone through in every action taken to support the families affected by recent...
Singapore’s IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations
SINGAPORE, Dec. 6, 2024 /PRNewswire/ -- IMAGINE AI is the largest calendar event in Singapore that brings together the brightest minds in healthcare and artificial intelligence to explore the transformative potential of AI in healthcare. Hosted at the Marina Bay Sands Expo & Convention Centre, this biennial event features a diverse...
SD Biosensor Signs Tripartite MOU for R&D of New Products for Extensively Drug-Resistant Tuberculosis with Japan’s RIT/JATA and Korea’s International Tuberculosis Research Center
SD Biosensor strengthens its new product lineup with the POC molecular diagnostic platform M10 Early detection of patients is expected to contribute to the eradication of tuberculosis in high-risk Asian countries SEOUL, South Korea, Dec. 6, 2024 /PRNewswire/ -- SD Biosensor, Inc. (KQ137310), South Korea's global in-vitro diagnostics company, announced the signing of a tripartite memorandum of understanding...
